Compagnie Lombard Odier SCmA Raises Stock Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Compagnie Lombard Odier SCmA grew its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 46.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,775 shares of the medical equipment provider’s stock after buying an additional 1,192 shares during the quarter. Compagnie Lombard Odier SCmA’s holdings in Intuitive Surgical were worth $1,970,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Berbice Capital Management LLC purchased a new stake in Intuitive Surgical in the fourth quarter worth about $26,000. Godsey & Gibb Inc. boosted its stake in shares of Intuitive Surgical by 140.0% in the third quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock worth $29,000 after acquiring an additional 35 shares during the period. MidAtlantic Capital Management Inc. bought a new position in shares of Intuitive Surgical in the third quarter worth about $33,000. Decker Retirement Planning Inc. bought a new position in shares of Intuitive Surgical in the fourth quarter worth about $36,000. Finally, Capital Performance Advisors LLP bought a new position in shares of Intuitive Surgical in the third quarter worth about $38,000. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Price Performance

NASDAQ:ISRG opened at $591.39 on Friday. The firm has a market capitalization of $210.64 billion, a price-to-earnings ratio of 92.26, a PEG ratio of 5.67 and a beta of 1.39. Intuitive Surgical, Inc. has a 1 year low of $364.17 and a 1 year high of $616.00. The business has a 50 day simple moving average of $557.70 and a 200-day simple moving average of $517.49.

Insider Activity

In other news, CFO Jamie Samath sold 108 shares of the stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $542.06, for a total value of $58,542.48. Following the sale, the chief financial officer now directly owns 8,757 shares in the company, valued at approximately $4,746,819.42. This represents a 1.22 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Amal M. Johnson sold 4,635 shares of the stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $566.60, for a total value of $2,626,191.00. Following the completion of the sale, the director now owns 12,275 shares in the company, valued at approximately $6,955,015. The trade was a 27.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 6,348 shares of company stock valued at $3,587,582 in the last ninety days. Insiders own 0.90% of the company’s stock.

Wall Street Analysts Forecast Growth

ISRG has been the subject of a number of recent analyst reports. UBS Group upped their price objective on Intuitive Surgical from $500.00 to $560.00 and gave the stock a “neutral” rating in a research note on Monday, January 27th. Stifel Nicolaus upped their price objective on Intuitive Surgical from $525.00 to $610.00 and gave the stock a “buy” rating in a research note on Thursday, December 5th. Piper Sandler reaffirmed an “overweight” rating and issued a $670.00 price objective (up previously from $538.00) on shares of Intuitive Surgical in a research note on Friday, January 24th. Barclays upped their price objective on Intuitive Surgical from $610.00 to $674.00 in a research note on Monday, January 27th. Finally, Citigroup upped their price objective on Intuitive Surgical from $640.00 to $711.00 and gave the stock a “buy” rating in a research note on Friday, January 24th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $613.10.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.